Prolyl isomerase Pin1 as a molecular target for cancer diagnostics and therapeutics

被引：117

作者：

Lu, KP ^{[1
]}

机构：

[1] Harvard Univ, Beth Israel Deaconess Med Ctr, Dept Med, Div Hematol Oncol,Canc Biol Program, Boston, MA 02215 USA

来源：

CANCER CELL | 2003年 / 4卷 / 03期

关键词：

D O I：

10.1016/S1535-6108(03)00218-6

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

[No abstract available]

引用

页码：175 / 180

页数：6

共 35 条

[1]

AYALA G, 2003, IN PRESS CANC RES

[2] Oncogenic kinase signalling [J].

Blume-Jensen, P ;

Hunter, T .

NATURE, 2001, 411 (6835) :355-365

[3] Juglone, an inhibitor of the peptidyl-prolyl isomerase Pin1, also directly blocks transcription [J].

Chao, SH ;

Greenleaf, AL ;

Price, DH .

NUCLEIC ACIDS RESEARCH, 2001, 29 (03) :767-773

[4] Practical management of patients with chronic myeloid leukemia receiving imatinib [J].

Deininger, MWN ;

O'Brien, SG ;

Ford, JM ;

Druker, BJ .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (08) :1637-1647

[5] Delineation of prognostic biomarkers in prostate cancer [J].

Dhanasekaran, SM ;

Barrette, TR ;

Ghosh, D ;

Shah, R ;

Varambally, S ;

Kurachi, K ;

Pienta, KJ ;

Rubin, MA ;

Chinnaiyan, AM .

NATURE, 2001, 412 (6849) :822-826

[6] Perspectives on the development of a molecularly targeted agent [J].

Druker, BJ .

CANCER CELL, 2002, 1 (01) :31-36

[7] Mice lacking Pin1 develop normally, but are defective in entering cell cycle from G0 arrest [J].

Fujimori, F ;

Takahashi, K ;

Uchida, C ;

Uchida, T .

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1999, 265 (03) :658-663

[8] The development and clinical use of trastuzumab (Herceptin) [J].

Harries, M ;

Smith, I .

[9] Selective inactivation of parvulin-like peptidyl-prolyl cis/trans isomerases by juglone [J].

Hennig, L ;

Christner, C ;

Kipping, M ;

Schelbert, B ;

Rücknagel, KP ;

Grabley, S ;

Küllertz, G ;

Fischer, G .

BIOCHEMISTRY, 1998, 37 (17) :5953-5960

[10] Prolyl isomerases and nuclear function [J].

Hunter, T .

CELL, 1998, 92 (02) :141-143

← 1 2 3 4 →